Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)

Clinical trial NCT04895358 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04895358
Sponsor: Merck Sharp & Dohme LLC
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Breast Neoplasms

Start date: 2021-06-18
Primary completion: 2026-04-24
Enrollment: 342

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.